Anupam Rama
Stock Analyst at JP Morgan
(4.43)
# 326
Out of 5,115 analysts
310
Total ratings
50%
Success rate
21.01%
Average return
Main Sectors:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintains: Overweight | $99 → $96 | $55.67 | +72.44% | 12 | Dec 19, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $65 → $67 | $39.73 | +68.64% | 9 | Dec 19, 2025 | |
| VOR Vor Biopharma | Maintains: Overweight | $43 → $40 | $14.53 | +175.29% | 2 | Dec 19, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $147 → $145 | $105.96 | +36.85% | 7 | Dec 19, 2025 | |
| NVAX Novavax | Maintains: Underweight | $7 → $6 | $6.94 | -13.54% | 1 | Nov 18, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $17 → $20 | $8.43 | +137.25% | 7 | Nov 18, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $29 → $32 | $27.45 | +16.58% | 6 | Nov 18, 2025 | |
| ENTA Enanta Pharmaceuticals | Initiates: Overweight | $17 | $16.60 | +2.41% | 1 | Nov 14, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $40 → $33 | $21.60 | +52.78% | 11 | Nov 12, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $55 → $57 | $35.84 | +59.04% | 10 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $27 | $9.60 | +181.25% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $77 | $76.53 | +0.61% | 12 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $14.25 | +33.33% | 14 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $11 | $5.90 | +86.44% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $36 | $25.16 | +43.08% | 18 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $171 → $179 | $146.93 | +21.83% | 19 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $24 | $31.08 | -22.78% | 8 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $35.69 | +121.35% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 | $10.09 | +9.02% | 12 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $220.86 | -9.44% | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $37 | $42.15 | -12.21% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.92 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $22.32 | +7.53% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $50.01 | +59.97% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $117 | $34.58 | +238.35% | 3 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $18.58 | +174.49% | 12 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $40.28 | +9.24% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $42.49 | -5.86% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.57 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.72 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.40 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $5.18 | +150.97% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $90 | $5.63 | +1,500.00% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $17.59 | +1,321.26% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.25 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $64.18 | -9.63% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $18.73 | -35.93% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $6.11 | +505.56% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $88.84 | -38.09% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $14 → $38 | $10.25 | +270.73% | 13 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $3.43 | +716.33% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $29.17 | +85.12% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.72 | +6,115.47% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $20.37 | +32.55% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $400.69 | -65.81% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $10.19 | +371.05% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $15.38 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.14 | +2,531.58% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $78.37 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.26 | - | 2 | Jul 21, 2017 |
Vera Therapeutics
Dec 19, 2025
Maintains: Overweight
Price Target: $99 → $96
Current: $55.67
Upside: +72.44%
Cogent Biosciences
Dec 19, 2025
Maintains: Overweight
Price Target: $65 → $67
Current: $39.73
Upside: +68.64%
Vor Biopharma
Dec 19, 2025
Maintains: Overweight
Price Target: $43 → $40
Current: $14.53
Upside: +175.29%
Nuvalent
Dec 19, 2025
Maintains: Overweight
Price Target: $147 → $145
Current: $105.96
Upside: +36.85%
Novavax
Nov 18, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $6.94
Upside: -13.54%
ORIC Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $8.43
Upside: +137.25%
Olema Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $29 → $32
Current: $27.45
Upside: +16.58%
Enanta Pharmaceuticals
Nov 14, 2025
Initiates: Overweight
Price Target: $17
Current: $16.60
Upside: +2.41%
Syndax Pharmaceuticals
Nov 12, 2025
Maintains: Overweight
Price Target: $40 → $33
Current: $21.60
Upside: +52.78%
RAPT Therapeutics
Nov 12, 2025
Maintains: Overweight
Price Target: $55 → $57
Current: $35.84
Upside: +59.04%
Nov 7, 2025
Maintains: Overweight
Price Target: $26 → $27
Current: $9.60
Upside: +181.25%
Nov 7, 2025
Maintains: Overweight
Price Target: $76 → $77
Current: $76.53
Upside: +0.61%
Nov 6, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $14.25
Upside: +33.33%
Nov 5, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $5.90
Upside: +86.44%
Nov 5, 2025
Maintains: Overweight
Price Target: $40 → $36
Current: $25.16
Upside: +43.08%
Nov 3, 2025
Maintains: Overweight
Price Target: $171 → $179
Current: $146.93
Upside: +21.83%
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $31.08
Upside: -22.78%
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $35.69
Upside: +121.35%
Oct 20, 2025
Upgrades: Neutral
Price Target: $11
Current: $10.09
Upside: +9.02%
Oct 10, 2025
Initiates: Overweight
Price Target: $200
Current: $220.86
Upside: -9.44%
Sep 29, 2025
Maintains: Overweight
Price Target: $27 → $37
Current: $42.15
Upside: -12.21%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $5.92
Upside: -
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $22.32
Upside: +7.53%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $50.01
Upside: +59.97%
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $34.58
Upside: +238.35%
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $18.58
Upside: +174.49%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $40.28
Upside: +9.24%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $42.49
Upside: -5.86%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.57
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.72
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $4.40
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $5.18
Upside: +150.97%
Aug 16, 2023
Maintains: Neutral
Price Target: $80 → $90
Current: $5.63
Upside: +1,500.00%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $17.59
Upside: +1,321.26%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $11.25
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $64.18
Upside: -9.63%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $18.73
Upside: -35.93%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $6.11
Upside: +505.56%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $88.84
Upside: -38.09%
Oct 11, 2021
Upgrades: Neutral
Price Target: $14 → $38
Current: $10.25
Upside: +270.73%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $3.43
Upside: +716.33%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $29.17
Upside: +85.12%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.72
Upside: +6,115.47%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $20.37
Upside: +32.55%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $400.69
Upside: -65.81%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $10.19
Upside: +371.05%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $15.38
Upside: -
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.14
Upside: +2,531.58%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $78.37
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.26
Upside: -